Advaxis Begins Patient Education Initiative to Promote Better Understanding of Cervical Cancer Vaccines; Vice President of Clinical Development Interviewed by Television Stations Nationwide.

NORTH BRUNSWICK, N.J. -- Television stations across the country recently interviewed Dr. John Rothman, Vice President of Clinical Development for Advaxis, Inc. (OTCBB: ADXS), a developer of Listeria-based cancer vaccines. These interviews were part of the Company's extensive program to help educate the public on the differences between the current prophylactic or preventative vaccines and next generation therapeutic vaccines being developed by Advaxis.

The Company recently initiated Phase I/II clinical testing with its lead Listeria-based therapeutic cancer vaccine, Lovaxin C, which targets cervical cancer caused by the human papilloma virus (HPV). Women already with cervical cancer or infected with the virus cannot benefit from the current prophylactic vaccines on the market.

In his interviews, Dr. Rothman discussed the immune system's role in fighting cancer. Researchers have made an important observation regarding the potential of the immune response that is directed against Listeria and feel is a key component in the treatment of cancer. Pre-clinical data for Lovaxin C has demonstrated a robust immune response to tumors upon administration of the drug and eradication of tumors in more than half of the animals tested. Listeria is a common microorganism that humans are exposed to through diet.

"Cervical cancer is the second leading cause of cancer deaths worldwide in women under fifty," said Dr. Rothman on-camera. "Being able to use a microorganism that provokes such an intense immune response to treat cancer has shown to be promising." Among the television stations featuring Dr. Rothman were WBFF/FOX in Baltimore, WISN/ABC in Milwaukee and KAAL/ABC in Austin.

Those interested in receiving a CD of the aired interviews may submit their request to [e-mail].

About Advaxis

Based in North Brunswick, New Jersey. Advaxis is developing proprietary Listeria cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania, and chair person of Advaxis' Scientific Advisory Board. Advaxis' is developing therapeutic cancer vaccines that enhance the immune system's cancer-fighting abilities through its proprietary Listeria monocytogenes based system, which utilizes two immunological mechanisms (Innate and Classical Immunity) to develop safer and more effective Listeria based cancer vaccines. Advaxis is the exclusive licensee of a patented broadly enabling Listeria platform technology that can elicit effective anti-tumor responses. Advaxis' lead Listeria vaccine candidate, Lovaxin C, targets cervical and head and neck cancers. Further Listeria vaccines in development target breast, ovarian and lung cancers. Advaxis has entered a Phase I/II clinical trial. The Listeria platform will also have applications in the fields of infectious disease and autoimmune disorders.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.